Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform
Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform
加拉帕戈斯和Adaptimmune进入临床合作，使用分散式制造平台许可下一代TCR T细胞疗法治疗癌症
- Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer
- Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform
- Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development
- Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales
- Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications
- Adaptimmune 和 Galapagos 将进行临床概念验证试验，以评估在加拉帕戈斯去中心化制造平台上生产的 uza-cel（下一代 MAGE-A4 TCR T 细胞疗法）对头颈癌患者的安全性和有效性
- 在使用Adaptimmune集中制造平台进行的一期试验中，Uza-Cel在头颈部癌症方面显示出令人鼓舞的结果，迄今为止，有五分之四的患者出现了部分反应
- 初始的 体外 对加拉帕戈斯去中心化制造平台上生产的uza-cel的测试显示，令人鼓舞的数据支持进一步的临床开发
- Adaptimmune将获得1亿美元的初始付款，包括7,000万美元的预付款和3000万美元的研发资金、高达1亿美元的期权行使费、最高4.65亿美元的额外开发和销售里程碑付款，外加净销售额的分级特许权使用费
- 加拉帕戈斯已获准独家许可 uza-cel，用于头颈癌以及未来潜在实体瘤癌适应症的全球开发和商业化